OncRef

Clinical Trial: NCT06400225

Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 2

Lead Sponsor:National Cancer Institute (NCI)
Information Provided By:National Cancer Institute (NCI)
Last Update Posted:2026-10-15

Study Overview

Brief Summary

This phase II MATCH treatment trial tests how well BVD-523FB (ulixertinib) works in treating patients with cancer that has certain genetic changes. BVD-523FB (ulixertinib) is used in patients whose cancer has a mutated (changed) form of a gene called BRAF. It is in a class of medications called kinase inhibitors. It works by blocking the action of proteins that signal cancer cells to multiply. This helps slow or stop the spread of cancer cells.

Official Title

MATCH Treatment Subprotocol Z1L: BVD-523FB (Ulixertinib) in Patients With Tumors With BRAF Fusions, or With Non-V600E, Non-V600K BRAF Mutations

Conditions

Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma

Intervention / Treatment

  • Procedure: Biopsy Procedure
  • Procedure: Biospecimen Collection
  • Procedure: Computed Tomography
  • Procedure: Echocardiography Test
  • Procedure: Magnetic Resonance Imaging
  • Procedure: Radionuclide Imaging
  • Drug: Ulixertinib

Other Study ID Numbers

  • NCI-2024-01160
  • NCI-2024-01160
  • EAY131-Z1L
  • EAY131-Z1L
  • U10CA180820

Start Date (Actual)

2019-07-24

Primary Completion Date (Actual)

2021-10-15

Study Completion Date (Estimated)

2026-12-31

Enrollment (Estimated)

35

Study Type

Interventional

Phase

Phase 2